Compare Royal Bank of Canada (RY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Twist Bioscience Corp — how do they compare? Royal Bank of Canada trades at $191.98 (market cap $262.99B), while Twist Bioscience Corp trades at $160.9 (market cap $10.08B). The key difference: Royal Bank of Canada is far larger — about 26.1× Twist Bioscience Corp's market cap, and Royal Bank of Canada pays a 2.66% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 47 Days and Twist Bioscience Corp for 27 Days on average.
| RY | TWST | |
|---|---|---|
Market Cap | $262.99B | $10.08B |
Volume | 1,016,377 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $217.87 | $205.00 |
52-Week Low | $143.64 | $25.45 |
Typical Hold Time | 47 Days | 27 Days |
Enterprise Value | $730.11B | $10.01B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $191.91, up 0.36% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.07 exceeding expectations, while revenue grew to $66.53B in 2025. Analyst sentiment is mixed with 43% buy ratings, though technical indicators show oversold conditions with RSI at 18.28.
RY presents a value opportunity with reasonable P/E of 17.08 and strong ROE of 17.2%, but faces technical headwinds and stretched valuations in the banking sector. The stock's 32% net margin and dividend yield around 3.7% support income investors, while near-term resistance at $192 may limit upside without fundamental catalysts.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
